6-Day Rally Sends DexCom Stock Up 25%
DexCom (DXCM) – a developer and seller of continuous glucose monitoring systems – hit a 6-day winning streak, with cumulative gains over this period amounting to 25%. The company’s market cap has surged by about $5.5 Bil over the last 6 days and currently stands at $28 Bil.
Is this an opportunity or a trap? There is not much to fear in DXCM stock given its overall Strong operating performance and financial condition. This is aligned with the stock’s High valuation because of which we think it is Fairly Priced (For details, see Buy or Sell DXCM).
But here is the interesting part. You are reading about this 25% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Is Booking Stock Undervalued Stock Or Value Trap?
- Decoding PLTR Stock’s Premium Valuation
- Intuit Stock: Strong Cash Flow Poised for a Re-Rating?
- Five-Year Tally: Lowe’s Companies Stock Delivers $50 Bil Gain
- Five-Year Tally: Mastercard Stock Delivers $60 Bil Gain
- Palantir Technologies Stock Hits Key Support – Buying Opportunity?
The following table summarizes the return for DXCM stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | DXCM | S&P 500 |
|---|---|---|
| 1D | 0.3% | 0.4% |
| 6D (Current Streak) | 24.7% | -0.4% |
| 1M (21D) | 15.0% | 5.1% |
| 3M (63D) | -1.6% | 9.3% |
| YTD 2026 | 8.6% | 9.2% |
| 2025 | -14.7% | 16.4% |
| 2024 | -37.3% | 23.3% |
| 2023 | 9.6% | 24.2% |
However, big gains can follow sharp reversals – but how has DXCM behaved after prior drops? See DXCM Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 147 S&P constituents with 3 days or more of consecutive gains and 15 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 109 | 9 |
| 4D | 10 | 3 |
| 5D | 26 | 2 |
| 6D | 2 | 1 |
| 7D or more | 0 | 0 |
| Total >=3 D | 147 | 15 |
Key Financials for DexCom (DXCM)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $4.0 Bil | $4.7 Bil |
| Operating Income | $600.0 Mil | $911.8 Mil |
| Net Income | $576.2 Mil | $836.3 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $1.3 Bil | $1.2 Bil |
| Operating Income | $323.0 Mil | $255.3 Mil |
| Net Income | $267.3 Mil | $199.5 Mil |
While DXCM stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.